Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 25%GRADE not reported 3 · 37.5%Very low 1 · 12.5%Low 1 · 12.5%Moderate 1 · 12.5%High 0 · 0%

Class I and/or III antiarrhythmics vs control

Outcomes at > 3 to 6 months after ablation · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class I and/or III antiarrhythmics vs control

Recurrence of atrial tachyarrhythmias · Human trial participants undergoing ablation for atrial fibrillation

Class I and/or III antiarrhythmics probably leads to lower recurrence of atrial tachyarrhythmias compared with control (moderate certainty).

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
RR 0.85 [0.78, 0.93]
5 studies · 2591 participants
Moderate

Class I and/or III antiarrhythmics vs control

Adverse events: thromboembolic events · Human trial participants undergoing ablation for atrial fibrillation

It is very uncertain whether class I and/or III antiarrhythmics changes adverse events: thromboembolic events compared with control (very low certainty).

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
Peto OR 0.96 [0.06, 15.5]
1 study · 212 participants
Very low

Class I and/or III antiarrhythmics vs control

Adverse events: myocardial infarction · Human trial participants undergoing ablation for atrial fibrillation

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
3 participants
GRADE not reported

Class I and/or III antiarrhythmics vs control

Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class I and/or III antiarrhythmics vs control

Adverse events: requirement for 1 or more hospitalisations for atrial tachyarrhythmia · Human trial participants undergoing ablation for atrial fibrillation

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
3 participants
GRADE not reported

Class I and/or III antiarrhythmics vs control

All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation

Class I and/or III antiarrhythmics showed no clear difference in all‐cause mortality compared with control (low certainty).

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
Peto OR 1 [0.06, 16.24]
1 study · 90 participants
Low

Class I and/or III antiarrhythmics vs control

Requirement for 1 or more repeat ablation · Human trial participants undergoing ablation for atrial fibrillation

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
3 participants
GRADE not reported